ACLX
Price
$68.31
Change
+$0.05 (+0.07%)
Updated
Jan 30 closing price
Capitalization
3.96B
24 days until earnings call
Intraday BUY SELL Signals
ZVRA
Price
$9.00
Change
+$0.14 (+1.58%)
Updated
Jan 30 closing price
Capitalization
507.24M
37 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ACLX vs ZVRA

Header iconACLX vs ZVRA Comparison
Open Charts ACLX vs ZVRABanner chart's image
Arcellx
Price$68.31
Change+$0.05 (+0.07%)
Volume$842.01K
Capitalization3.96B
Zevra Therapeutics
Price$9.00
Change+$0.14 (+1.58%)
Volume$716.46K
Capitalization507.24M
ACLX vs ZVRA Comparison Chart in %
ACLX
Daily Signal:
Gain/Loss:
ZVRA
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ACLX vs. ZVRA commentary
Feb 02, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACLX is a Hold and ZVRA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 02, 2026
Stock price -- (ACLX: $68.31 vs. ZVRA: $9.00)
Brand notoriety: ACLX and ZVRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACLX: 78% vs. ZVRA: 73%
Market capitalization -- ACLX: $3.96B vs. ZVRA: $507.24M
ACLX [@Biotechnology] is valued at $3.96B. ZVRA’s [@Biotechnology] market capitalization is $507.24M. The market cap for tickers in the [@Biotechnology] industry ranges from $119.22B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACLX’s FA Score shows that 0 FA rating(s) are green whileZVRA’s FA Score has 1 green FA rating(s).

  • ACLX’s FA Score: 0 green, 5 red.
  • ZVRA’s FA Score: 1 green, 4 red.
According to our system of comparison, ZVRA is a better buy in the long-term than ACLX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACLX’s TA Score shows that 4 TA indicator(s) are bullish while ZVRA’s TA Score has 6 bullish TA indicator(s).

  • ACLX’s TA Score: 4 bullish, 5 bearish.
  • ZVRA’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, ZVRA is a better buy in the short-term than ACLX.

Price Growth

ACLX (@Biotechnology) experienced а +0.90% price change this week, while ZVRA (@Biotechnology) price change was +0.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.27%. For the same industry, the average monthly price growth was +3.46%, and the average quarterly price growth was +33.81%.

Reported Earning Dates

ACLX is expected to report earnings on Feb 26, 2026.

ZVRA is expected to report earnings on Mar 11, 2026.

Industries' Descriptions

@Biotechnology (-4.27% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACLX($3.96B) has a higher market cap than ZVRA($507M). ACLX YTD gains are higher at: 4.770 vs. ZVRA (0.446). ZVRA has higher annual earnings (EBITDA): 67.2M vs. ACLX (-209.52M). ACLX has more cash in the bank: 461M vs. ZVRA (200M). ACLX has less debt than ZVRA: ACLX (51.8M) vs ZVRA (62.7M). ZVRA has higher revenues than ACLX: ZVRA (84.4M) vs ACLX (35.9M).
ACLXZVRAACLX / ZVRA
Capitalization3.96B507M780%
EBITDA-209.52M67.2M-312%
Gain YTD4.7700.4461,068%
P/E RatioN/A19.15-
Revenue35.9M84.4M43%
Total Cash461M200M231%
Total Debt51.8M62.7M83%
FUNDAMENTALS RATINGS
ZVRA: Fundamental Ratings
ZVRA
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
80
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
26
PRICE GROWTH RATING
1..100
61
P/E GROWTH RATING
1..100
51
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ACLXZVRA
RSI
ODDS (%)
Bullish Trend 4 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
77%
Momentum
ODDS (%)
Bearish Trend 4 days ago
78%
Bearish Trend 4 days ago
80%
MACD
ODDS (%)
Bullish Trend 6 days ago
89%
Bullish Trend 4 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
88%
Bullish Trend 4 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
88%
Bullish Trend 4 days ago
77%
Advances
ODDS (%)
Bullish Trend 4 days ago
86%
Bullish Trend 4 days ago
80%
Declines
ODDS (%)
Bearish Trend 6 days ago
78%
Bearish Trend 6 days ago
76%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
79%
N/A
Aroon
ODDS (%)
Bearish Trend 4 days ago
74%
Bullish Trend 4 days ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
ACLX
Daily Signal:
Gain/Loss:
ZVRA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
REPIX40.840.05
+0.12%
ProFunds Real Estate UltraSector Inv
HCAYX58.61-0.25
-0.42%
Hartford Capital Appreciation Y
MUEAX39.06-0.23
-0.59%
MFS Blended Research Core Equity A
HOOCX27.16-0.23
-0.84%
Hartford Schroders US Small Cap Opps C
GDSRX27.22-0.42
-1.52%
Goldman Sachs Small Cap Eq Insghts R

ACLX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACLX has been loosely correlated with CGON. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ACLX jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACLX
1D Price
Change %
ACLX100%
+0.07%
CGON - ACLX
49%
Loosely correlated
-2.56%
KYMR - ACLX
45%
Loosely correlated
-1.65%
IDYA - ACLX
44%
Loosely correlated
-2.42%
NUVL - ACLX
44%
Loosely correlated
+0.45%
ROIV - ACLX
43%
Loosely correlated
-1.82%
More

ZVRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZVRA has been loosely correlated with ACLX. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ZVRA jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZVRA
1D Price
Change %
ZVRA100%
+1.58%
ACLX - ZVRA
38%
Loosely correlated
+0.07%
XERS - ZVRA
37%
Loosely correlated
+1.66%
AUTL - ZVRA
36%
Loosely correlated
-4.20%
FULC - ZVRA
35%
Loosely correlated
-1.92%
IMTX - ZVRA
34%
Loosely correlated
+1.81%
More